We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO) in connection with its proposed acquisition by United Therapeutics Corporation (NASDAQ: UTHR) via tender offer.  Under the merger agreement, the Company’s shareholders will receive $3.25 and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s manufactured kidney product by December 31, 2025.

Weiss Law is investigating whether the (i) Miromatrix board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the $3.25 merger consideration adequately compensates Miromatrix shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com